[1]. Clinical Outcome of Endoscopic Transpapillary Drainage for Biliary Obstruction Due to Non-Hepato-Pancreato-Biliary Cancer: A Two-Center Retrospective Cohort Study.
Clinics and practice [巻]16 [号]2 （2026年） [査読] 有
[2]. C-Reactive Protein Levels Predict Improvement in the Liver Functional Reserve by Long-Term Rifaximin Treatment.
Diseases (Basel, Switzerland) [巻]13 [号]10 （2025年） [査読] 有
[3]. 自己免疫性肝炎との鑑別に苦慮し,ステロイドへの治療反応性を契機に診断に至ったWilson病の一例
肝臓 (一社)日本肝臓学会 [巻]66 [号]7 [頁]282 -282-289 （2025年） [査読] 有
[DOI] [4]. Intrahepatic Cholangiocarcinoma with BRCA Mutation Achieved Pathological Complete Response after Neoadjuvant Gemcitabine, Cisplatin, and S-1 Therapy: A Case Report.
Surgical case reports [巻]11 [号]1 （2025年） [査読] 有
[DOI] [5]. Hepatic Angiosarcoma with Peliosis Hepatis.
Internal medicine (Tokyo, Japan) [巻]62 [号]8 [頁]1157 -1166 （2023年） [査読] 有
[DOI] [6]. Breach of tolerance versus burden of bile acids: Resolving the conundrum in the immunopathogenesis and natural history of primary biliary cholangitis.
Journal of autoimmunity [巻]136 [頁]103027 （2023年） [査読] 有
[DOI] [7]. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation.
Journal of clinical medicine [巻]12 [号]6 （2023年） [査読] 有
[DOI] [8]. Arg-Gly-Asp-binding integrins activate hepatic stellate cells via the hippo signaling pathway.
Cellular signalling [巻]99 [頁]110437 （2022年） [査読] 有
[DOI] [9]. Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C.
Hepatology communications （2022年） [査読] 有
[DOI] [10]. High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California.
Digestive diseases and sciences [巻]66 [号]8 [頁]2833 -2839 （2021年） [査読] 有
[DOI] [11]. Ursodeoxycholic acid impairs liver-infiltrating T-cell chemotaxis through IFN-γ and CX3CL1 production in primary biliary cholangitis.
European journal of immunology [巻]51 [号]6 [頁]1519 -1530 （2021年） [査読] 有
[DOI] [12]. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
Gut and liver [巻]12 [号]2 [頁]201 -207 （2018年） [査読] 有
[DOI] [13]. Critical role of CREBH-mediated induction of transforming growth factor β2 by hepatitis C virus infection in fibrogenic responses in hepatic stellate cells.
Hepatology (Baltimore, Md.) [巻]66 [号]5 [頁]1430 -1443 （2017年） [査読] 有
[DOI] [14]. Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research [巻]35 [号]12 [頁]956 -62 （2015年） [査読] 有
[DOI] [15]. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Internal medicine (Tokyo, Japan) [巻]54 [号]3 [頁]273 -9 （2015年） [査読] 有
[DOI] [16]. C型肝炎治療法の進歩
Uirusu [巻]65 [号]2 [頁]239 -244 （2015年） [査読] 無
[DOI] [17]. Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients.
ISRN hepatology [巻]2014 [頁]875140 （2014年） [査読] 有
[DOI]